When.com Web Search

  1. Ads

    related to: new treatments for dementia

Search results

  1. Results From The WOW.Com Content Network
  2. A Common Drug Could Lower Your Dementia Risk By 35 ... - AOL

    www.aol.com/common-drug-could-lower-dementia...

    After 670 days, there were 1,172 new diagnoses of dementia among the study participants. When compared with people who took DPP-4 inhibitors, those who took SGLT-2 inhibitors had a 35 percent ...

  3. Here Are the New Drugs and Treatments We Could See in 2024 - AOL

    www.aol.com/drugs-treatments-could-see-2024...

    Credit - Getty Images. 2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, and the first treatment based on the gene-editing technology ...

  4. Dementia Doctors Share The Changes They Would Make ... - AOL

    www.aol.com/dementia-doctors-share-changes-today...

    “Now, we have FDA-approved treatments and ways to reduce dementia risk that could make a difference,” says Dr. Kaiser. Keep reading for Dr. Kaiser’s and Dr. Ertekin-Taner’s top tips for ...

  5. Anti-amyloid drugs - Wikipedia

    en.wikipedia.org/wiki/Anti-amyloid_drugs

    Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...

  6. Lecanemab - Wikipedia

    en.wikipedia.org/wiki/Lecanemab

    Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [2] [4] Lecanemab is an amyloid beta-directed antibody. [2] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [2]

  7. Type 2 diabetes drugs could lower dementia, Parkinson's ... - AOL

    www.aol.com/type-2-drugs-could-lower-133000670.html

    The analysis showed that over a follow-up period of an average of 2.06 years for people on SGLT2 inhibitors, and 3.70 years for people on different antidiabetes drugs, there was a reduction in the ...

  1. Ads

    related to: new treatments for dementia